Genprex (GNPX) Featured in NetworkNewsWire Publication Summarizing Gene Therapy Treatment for Lung Cancer
NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — today announces its placement in an editorial published by ("NNW"), a multifaceted financial news and publishing company for private and public entities.
To view the full publication, titled “Gene Therapy Treatments Offer Hope for Cancer Patients,” visit:
Despite huge public awareness and a decrease in smoking, lung cancer remains one of the most common types of cancer and is a major killer in many countries. An estimated in 2018, and 1.76 million of them died. While prevention has improved, survival rates remain low once the disease takes root.
Tackling cancer has become a huge issue for modern governments, charities and health-care businesses. Companies such as ) have put the whole focus of their operations on tackling the disease. Whether aimed at curing the disease or extending the lives of patients, these treatments are varied and often innovative. But the very nature of cancer, in which a body’s own cells destroy it, makes this difficult.
About Genprex Inc.
Genprex Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell-signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at or follow Genprex on Twitter at , Facebook at and LinkedIn at .
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with . As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit .
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: .
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications:
NetworkWire (NW)
New York, New York
212.418.1217 Office
